Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

Table. 4 Evolution of cardiovascular risk

A. TDF/TDF group, Mean [95% CI]
	N	2016	2018	Evolution 2018–2016	p-value
DAD-R	26	1.8 [1.3;2.7]^(a)	1.9 [1.3;2.7]^(a)	0.20 [− 0.19;0.59]	0.32

B. TDF/TAF group, Mean [95%CI]
	N	Before (on TDF)	After (on TAF)	Evolution After–Before	p-value
DAD-R	64	1.6 [1.2;2.1]^(a)	1.8[1.4;2.4]^(a)	0.43 [0.090;0.76]	0.0008

^(a) Given the right skew of DAD-R, mean and 95%IC were calculated using log transformation. The results were back-transformed to the original scale

ISSN: 1471-2334